Market closedNon-fractional
UroGen Pharma/URGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
URGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Princeton, United States
Employees
204
Website
www.urogen.com
UroGen Pharma Metrics
BasicAdvanced
$618M
Market cap
-
P/E ratio
-$3.33
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$618M
Beta
1.09
Financial strength
Current ratio
7.47
Quick ratio
6.765
Long term debt to equity
-244.748
Total debt to equity
-246.689
Interest coverage (TTM)
-5.09%
Management effectiveness
Return on assets (TTM)
-27.60%
Return on equity (TTM)
133.15%
Valuation
Price to revenue (TTM)
5.584
Price to book
-13.57
Price to tangible book (TTM)
-13.57
Price to free cash flow (TTM)
-5.707
Growth
Revenue change (TTM)
24.00%
Earnings per share change (TTM)
-31.54%
3-year revenue growth
63.51%
3-year earnings per share growth
-14.32%
What the Analysts think about UroGen Pharma
Analyst Ratings
Majority rating from 5 analysts.
UroGen Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$19M
-20.43%
Net income
-$32M
23.85%
Profit margin
-172.19%
55.64%
UroGen Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.03
-$0.68
-$0.72
-$0.97
-
Expected
-$1.14
-$0.85
-$0.68
-$0.87
-$0.85
Surprise
-9.33%
-19.62%
5.88%
12.01%
-
UroGen Pharma News
AllArticlesVideos
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Business Wire·3 weeks ago
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewsWire·3 weeks ago
Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $618M as of July 05, 2024.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of July 05, 2024.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell UroGen Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.